Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins.
Hojjat Jodaylami M, Djaïleb A, Ricard P, Lavallée É, Cellier-Goetghebeur S, Parker MF, Coutu J, Stuible M, Gervais C, Durocher Y, Desautels F, Cayer MP, de Grandmont MJ, Rochette S, Brouard D, Trottier S, Boudreau D, Pelletier JN, Masson JF. Hojjat Jodaylami M, et al. Among authors: gervais c. Sci Rep. 2021 Nov 19;11(1):22912. doi: 10.1038/s41598-021-02484-9. Sci Rep. 2021. PMID: 34799675 Free PMC article. No abstract available.
Transient Gene Expression in Suspension HEK293-EBNA1 Cells.
L'Abbé D, Bisson L, Gervais C, Grazzini E, Durocher Y. L'Abbé D, et al. Among authors: gervais c. Methods Mol Biol. 2018;1850:1-16. doi: 10.1007/978-1-4939-8730-6_1. Methods Mol Biol. 2018. PMID: 30242676
Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals.
Djaileb A, Hojjat Jodaylami M, Coutu J, Ricard P, Lamarre M, Rochet L, Cellier-Goetghebeur S, Macaulay D, Charron B, Lavallée É, Thibault V, Stevenson K, Forest S, Live LS, Abonnenc N, Guedon A, Quessy P, Lemay JF, Farnós O, Kamen A, Stuible M, Gervais C, Durocher Y, Cholette F, Mesa C, Kim J, Cayer MP, de Grandmont MJ, Brouard D, Trottier S, Boudreau D, Pelletier JN, Masson JF. Djaileb A, et al. Among authors: gervais c. Analyst. 2021 Jul 26;146(15):4905-4917. doi: 10.1039/d1an00893e. Analyst. 2021. PMID: 34250530
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins.
Hojjat Jodaylami M, Djaïleb A, Ricard P, Lavallée É, Cellier-Goetghebeur S, Parker MF, Coutu J, Stuible M, Gervais C, Durocher Y, Desautels F, Cayer MP, de Grandmont MJ, Rochette S, Brouard D, Trottier S, Boudreau D, Pelletier JN, Masson JF. Hojjat Jodaylami M, et al. Among authors: gervais c. Sci Rep. 2021 Nov 8;11(1):21601. doi: 10.1038/s41598-021-00844-z. Sci Rep. 2021. PMID: 34750399 Free PMC article.
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.
Akache B, Renner TM, Tran A, Deschatelets L, Dudani R, Harrison BA, Duque D, Haukenfrers J, Rossotti MA, Gaudreault F, Hemraz UD, Lam E, Régnier S, Chen W, Gervais C, Stuible M, Krishnan L, Durocher Y, McCluskie MJ. Akache B, et al. Among authors: gervais c. Sci Rep. 2021 Nov 8;11(1):21849. doi: 10.1038/s41598-021-01363-7. Sci Rep. 2021. PMID: 34750472 Free PMC article.
A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination.
Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, Abe KT, Wang JH, Pasculescu A, Maltseva M, Rocheleau L, Pelchat M, Fazel-Zarandi M, Iskilova M, Barrios-Rodiles M, Bennett L, Yau K, Cholette F, Mesa C, Li AX, Paterson A, Hladunewich MA, Goodwin PJ, Wrana JL, Drews SJ, Mubareka S, McGeer AJ, Kim J, Langlois MA, Gingras AC, Durocher Y. Colwill K, et al. Among authors: gervais c. Clin Transl Immunology. 2022 Mar 23;11(3):e1380. doi: 10.1002/cti2.1380. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35356067 Free PMC article.
Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models.
Rossotti MA, van Faassen H, Tran AT, Sheff J, Sandhu JK, Duque D, Hewitt M, Wen X, Bavananthasivam J, Beitari S, Matte K, Laroche G, Giguère PM, Gervais C, Stuible M, Guimond J, Perret S, Hussack G, Langlois MA, Durocher Y, Tanha J. Rossotti MA, et al. Among authors: gervais c. Commun Biol. 2022 Sep 9;5(1):933. doi: 10.1038/s42003-022-03866-z. Commun Biol. 2022. PMID: 36085335 Free PMC article.
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.
Akache B, Renner TM, Stuible M, Rohani N, Cepero-Donates Y, Deschatelets L, Dudani R, Harrison BA, Gervais C, Hill JJ, Hemraz UD, Lam E, Régnier S, Lenferink AEG, Durocher Y, McCluskie MJ. Akache B, et al. Among authors: gervais c. NPJ Vaccines. 2022 Oct 12;7(1):118. doi: 10.1038/s41541-022-00540-7. NPJ Vaccines. 2022. PMID: 36224247 Free PMC article.
Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance.
Djaïleb A, Lavallée É, Parker MF, Cayer MP, Desautels F, de Grandmont MJ, Stuible M, Gervais C, Durocher Y, Trottier S, Boudreau D, Masson JF, Brouard D, Pelletier JN. Djaïleb A, et al. Among authors: gervais c. Front Immunol. 2023 Jan 20;13:1052424. doi: 10.3389/fimmu.2022.1052424. eCollection 2022. Front Immunol. 2023. PMID: 36741379 Free PMC article.
330 results